Schizophrenia.com

A potential new use for pomaglumetad methionil

This drug failed in larger schizophrenia trials. However, there was the suggestion that it worked in enough patients that another company bought the rights in order to develop biomarkers for who would be treatment responsive. This animal study suggests the drug could be used as a preventative.

These results suggest that peripubertal mGluR2/3 agonist administration can prevent the emergence of vHPC pyramidal neuron hyperactivity and increased DA neuron population activity in adult MAM rats.

2 Likes